Metformin is widely prescribed as the first-line pharmacologic therapy for type 2 diabetes mellitus (DM2). Despite its broad use, its safety profile in older adults (aged ≥65 years) requires critical evaluation due to age-related physiological changes, polypharmacy, and comorbidities common in this population. Objective To assess the safety of metf
73 Reached
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes
Short-term Insulin Therapy for better Glycemic Control
14 Reached5 Comments6 Likes
Autoimmune Hepatitis in Girl with T1DM
1153 Reached2 Comments4 Likes
Risk Factors Associated Glycemia in LBW Infants
2793 Reached2 Comments1 Likes
Link between PCOS, Obesity and Diabetes
477 Reached2 Likes